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Abstract 
 
Lung Cancer is the number one cause of death by cancer worldwide in both genders 
and Non-Small Cell Lung Cancer represents the majority of Lung Cancer cases. The 
treatment for this cancer is planned with base on the TNM stage, the presence of some 
alterations that may allow targeted therapies to be used and recently the use of 
immunotherapies. However, the precise selection of the treatment is still a problem in this 
cancer as it is for many others. Not all patients benefit from all therapies and there are 
also differences in patients’ responses to the same therapy. In order to have a more 
efficient and precise therapy selection, the discovery of biomarkers and their influence and 
action is a vital approach. MMPs and TIMPs are thereby potential candidates to be used 
in the selection of anti-cancer therapies as they are very important in many processes of 
carcinogenesis such as inflammation and metastization. 
One of the methods used to study drug sensitivity and response is the use of LCLs 
from the patients. In these studies, the peripheral blood lymphocytes are immortalized 
using EBV virus in order to have an unlimited DNA and other biomolecules reservoir. It 
becomes interesting to hypothesize the importance of potential biomarkers such as MMPs 
and TIMPs in drug sensitivity and response in order to evaluate their influence and 
eventually consider them as candidates for therapy selection taking into consideration the 
patients’ characteristics. However, the transformation that occurs can raise a barrier to 
this possibility as the immortalization technique induces alterations to the cells that can 
change their behavior and biology. 
In this project, the mRNA levels of MMP-2, MMP-7, TIMP-2 and TIMP-4 were 
studied before and after the immortalization technique in order to understand if this 
method would induce significant changes to the levels of these MMPs and TIMPs. The 
results suggested that there were significant changes in the levels of MMP-2 and TIMP-2 
which means that the bioavailability of these biomolecules is greatly altered by this 
technique and therefore the study of their influence in drug sensitivity and response using 
LCLs as a model may not be possible. Both MMP-2 and TIMP-2 mRNA levels were found 
to be increased after the immortalization technique. This can be explained due to the use 
of EBV to immortalize the patients’ peripheral blood lymphocytes. In further studies it 
would be interesting to understand if these changes are related not only to cell growth but 
also to potential invasive and metastatic features in lymphoblastoid cells which would 
mean that eventually, EBV could induce processes similar to those that happen in 
carcinogenesis. The study of MMP-2 and TIMP-2 activities and protein levels in LCLs 
could give more insight on their influence in this context. These changes can not only be 
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potential limitations in LCLs based studies but also partially responsible for the difficulties 
on translating findings in LCLs to clinical practice. The levels of MMP-7 and TIMP-4 did 
not registered any significant change which leaves the possibility for them to be studied in 
this context further on. 
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Resumo 
 
O cancro do pulmão é a principal causa de morte por cancro no mundo em ambos 
os sexos e o cancro do pulmão de não-pequenas células representa a maioria dos casos. 
A escolha para o tratamento deste cancro baseia-se essencialmente no estadiamento 
TNM, na presença de algumas alterações que podem permitir o uso de terapias 
direcionadas e, mais recentemente, a utilização de imunoterapias. No entanto, a seleção 
do tratamento neste cancro para determinado doente, ainda não é tão efetiva e eficiente 
como desejaríamos, problema que é comum para muitos outros tipos de cancro. Nem 
todos os doentes beneficiam de determinadas terapias visto que muitas vezes existem 
diferenças na resposta dos mesmos face ao mesmo tipo de tratamento. Afim de melhorar 
e tornar a seleção das terapias mais eficaz, a descoberta de biomarcadores e da sua 
influência e ação é um tipo de abordagem fundamental. As metaloproteinases de matriz e 
os seus inibidores naturais são potenciais candidatos para serem utilizados na seleção de 
terapias contra o cancro uma vez que participam em muitos processos da carcinogénese, 
tais como a inflamação e a metastização. 
Um dos métodos utilizados para estudar a sensibilidade e resposta a fármacos é a 
utilização de linhas celulares linfoblastóides dos doentes. Nestes estudos, os linfócitos do 
sangue periférico são imortalizados utilizando o vírus Epstein-Barr com o objetivo de ter 
uma reserva e fonte ilimitada de DNA e outras biomoléculas. Como tal, torna-se 
interessante colocar a hipótese de estudar a importância e influência de biomoléculas 
como as MMPs e TIMPs no estudo da sensibilidade e resposta a fármacos e, 
eventualmente, considerá-las como potenciais biomarcadores para a seleção de terapias 
tendo em conta as caraterísticas dos doentes. No entanto, a transformação que ocorre 
pode ser um entrave visto que a técnica de imortalização induz alterações nas células 
que podem alterar a sua biologia e o seu comportamento. 
Neste projeto, os níveis de mRNA das MMP-2, MMP-7, TIMP-2 e TIMP-4, foram 
estudados antes e após a técnica de imortalização de modo a esclarecer se esta técnica 
realmente induz mudanças significativas nos níveis destas MMPs e TIMPs. Os resultados 
sugeriram que houve mudanças significativas nos níveis de MMP-2 e TIMP-2, o que 
significa que a disponibilidade destas biomoléculas é, de facto, alterada por este método 
e, por conseguinte, o estudo da sua influência na sensibilidade e resposta aos fármacos, 
utilizando as linhas linfoblastóides dos doentes como modelo, pode não ser possível. 
Ambos os níveis de mRNA das MMP-2 e TIMP-2 aumentaram significativamente após a 
técnica de imortalização. Isto pode indicar que o uso do vírus EBV para imortalizar 
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linfócitos do sangue periférico dos doentes provoca alterações significativas nos níveis de 
mRNA destas biomoléculas. Em estudos futuros, seria interessante perceber se estas 
mudanças estão relacionadas, não só com o crescimento celular, mas também com 
potenciais caraterísticas invasivas e metastáticas das células linfoblastóides. Tal 
significaria que o uso do vírus EBV poderia induzir processos semelhantes aos que 
acontecem na carcinogénese. O estudo das atividades e níveis proteicos das MMP-2 e 
TIMP-2 nas linhas linfoblastóides poderia fornecer mais informação e clarificar a 
influência das MMP-2 e TIMP-2 neste contexto. Estas alterações também podem ser 
potenciais limitações nos estudos que usam estas linhas celulares e podem justificar, em 
parte, as dificuldades em traduzir descobertas nestas linhas celulares para a prática 
clínica. Os níveis de MMP-7 e TIMP-4 não registaram qualquer alteração significativa o 
que deixa a possibilidade de poderem ser estudados neste contexto no futuro. 
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1 Introduction 
 
1.1 Cancer and Carcinogenesis  
Cancer is the 21st century disease, it is a vast, complex and interesting area of 
research. Its characteristics and statistics often alarm the general population worldwide 
but they also motivate the scientific community to increase their efforts in order to combat 
this complex disease. There are much data and information yet to discover but that must 
be perceived as many opportunities to study and improve our knowledge on cancer and 
ultimately improve the conditions and prognosis of cancer patients. 
The formation of cancer is often called carcinogenesis [1]. At first it occurs initiation 
which involves alteration, change or mutation of genes spontaneously or induced by 
exposure to a carcinogenic agent [2]. This leads to dysregulation of signaling pathways 
associated with cellular proliferation, survival and differentiation [2]. After initiation there is 
promotion, where the proliferation of preneoplastic cells is continuous and there is an 
accumulation of preneoplastic cells [2]. Progression is considered to be the stage between 
premalignant lesions and invasive cancer [2]. It is the final stage of neoplastic 
transformation where cell proliferation, genetic and phenotypic changes can occur [2]. At 
this stage there is a fast increase of tumor size where cells undergo into further alterations 
with invasive and metastatic potential [2]. Finally there is metastasis, which involves the 
spread of cancer cells from the primary tumor to other parts of the organism through 
bloodstream or lymphatic system [2].  
During the years the number of cancer survivors increased due to the aging and 
growth of populations and improvements in early diagnosis and treatment [3]. Cancer 
patients that are diagnosed at early stages tend to have a better chance of survival than 
those diagnosed at later stages [3].  
According to the World Health Organization, cancers are one of the leading causes 
of morbidity and mortality worldwide with approximately 14 million new cases and 8,2 
million cancer related deaths in 2012 [4]. The number of new cases is expected to rise by 
70% in the next two decades [4]. A third of cancer deaths are due to behavioral and 
dietary risks such as high body mass index, tobacco and alcohol use [4]. In fact tobacco 
smoke is the most important risk factor for cancer, causing around 20% of all cancer 
deaths and about 70% of lung cancer (LC) deaths [4]. 
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1.2 Lung Cancer 
There are two major forms of LC: Non-Small Cell Lung Cancer (NSCLC) about 85% 
of all LC cases and Small-Cell Lung Cancer (SCLC) counting approximately 15% [5]. The 
first can be divided in three major histological subtypes: Squamous cell carcinoma (SCC), 
Adenocarcinomas (ADC) and Large-cell lung cancer (LCC) [5]. The SCC and SCLC are 
usually developed in central airways and contrastingly, ADCs are developed in peripheral 
airways [5–7].  
LC risk is increased by genetic alterations that can be inherited such as rare 
mutations in p53 or retinoblastoma or mutations in epidermal growth factor receptor 
(EGFR) [5, 8–10]. Reduced DNA repair capacity accompanied by exposure to tobacco 
smoke is also very harmful and can result in driver mutations towards the formation of LC 
[5, 11]. 
In general, environmental factors such as tobacco smoke and genetic susceptibility 
interact to influence carcinogenesis [5, 12]. Nevertheless, there are unrelated factors to 
smoking which are also important to consider [5, 12].  
LC is the number one cause of death by cancer worldwide and the most incident 
cancer in both genders with 1824701 incidence cases and 1589925 deaths (Figure 1). LC 
is the most incident and mortal cancer for men with 1241601 incidence cases and 
1098702 deaths. As far as women are concerned, it is the third most common cancer with 
1671149 incidence cases and the second deadliest with 491223 deaths [13]. 
 
Figure 1 – Lung Cancer incidence and mortality Worldwide, both genders, all ages. GLOBOCAN 
2012 (IARC). 
In Europe, LC is the deadliest cancer and the third most incident in both genders 
with 410220 incidence cases and 353848 deaths (Figure 2). It is the leading cause of 
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death by cancer for men with 254706 deaths and the second most common with 290904 
incidence cases. As for women, LC is the third deadliest cancer with 99142 deaths and 
the third most common cancer 119316 incidence cases [13].  
 
Figure 2 - Lung Cancer incidence and mortality in Europe, both genders, all ages. GLOBOCAN 
2012 (IARC). 
In Portugal LC is the fourth most incident cancer with 4192 incidence cases but it 
is the second deadliest with 3441 deaths, once again in both genders (Figure 3). For men, 
LC is the third most common cancer with 3215 incidence cases and the deadliest cancer 
with 2638 deaths. For women, LC is the fifth most incident cancer with 977 incidence 
cases and the fourth deadliest with 803 deaths [13].  
 
Figure 3 - Lung Cancer incidence and mortality in Portugal, both genders, all ages. GLOBOCAN 
2012 (IARC). 
The greatest problem with this cancer is that 70% of patients are diagnosed at an 
advanced stage [14]. More than 50% of patients are diagnosed with a stage IV and the 
prognosis for all stages combined is still poor with a 5-year survival rate of 15% [15]. As 
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for patients with an early-stage or localized disease, 5-year-survival rates reach 
approximately 52% and patients with advanced disease or stage IV have a 5-year survival 
rate of less than 5% [15].  
It is well known that LC is a great cause of severe morbidity and mortality and 80-
90% of all LC cases are attributed to cigarrete smoking and could be prevented [16–18]. 
Smoking has been associated with LC for several years and it is without doubt a major 
risk factor [16–18]. Involuntary smoking or environmental tobacco smoke exposure is also 
associated with the risk of developing LC although the risk is not as great as for the active 
smokers [17].  
Environmental or occupational exposures to radiation, chemical agents, air 
pollution, asbestos, radon and others carcinogens are also associated with LC being 
important to 10-15% of never smokers who develop LC [17]. 
Family history of LC, genetic susceptibility, infectious agents and pulmonary 
diseases such as chronic obstructive pulmonary disease can also be risk factors to 
develop LC [17]. 
The treatment options for LC include surgery, radiation therapy, chemotherapy, 
target therapy and immunotherapy [19, 20]. Their application depends on many factors 
such as LC histological type and TNM stage in which the size of primary tumor (T), the 
presence of metastases in regional surrounding lymph nodes (N) and the presence of 
distant metastases (M) are the main drivers of choice of treatment [21]. Despite all the 
recent advances and improvements in diagnostic methods, technologies and therapies, in 
the case of LC they are still unsatisfactory because most patients are diagnosed at an 
advanced stage and treatment is not as effective as we would want [22].  
Most of LC patients are treated with platinum based chemotherapy, many times 
combined with gemcitabine, vinorelbine, pemetrexed or taxanes but this treatment is often 
associated with resistance due to acquired mutations [19, 20]. It is also known that factors 
such as stage of disease, histological type and smoking status can influence the response 
to treatment [19, 20]. 
 
 
1.3 Non-Small Cell Lung Cancer 
There are three main histological subtypes in NSCLC: ADCs which corresponds to 
approximately 50% of NSCLC cases followed by SCC with approximately 40% of the 
cases and finally LCC with approximately the remaining 10%  [23, 24]. 
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Generally, ADCs arise in distal airways while SCCs arise in more proximal airways 
and are strongly associated with smoking and chronic inflammation [23, 25, 26]. ADCs 
often have a glandular differentiation and express biomarkers consistent with the origin in 
distal areas of the lung [25, 26]. SCCs are characterized by a squamous differentiation 
and are distinguished from ADCs in immunostaining and/or transcription factors [25–27].  
LCC is normally diagnosed by exclusion, if the tumor cells do not appear to be either 
glandular or squamous in shape and there is no expression of biomarkers connected to 
them [23]. 
There are many gene mutations associated with NSCLC. EGFR overexpression is 
present in 43% to 83% of NSCLC cases and mutations in this gene, are present in 10% to 
15% of NSCLC patients. There is also a rearrangement of the ALK gene, most of the 
times resulting in an EML4-ALK fusion gene, that is present in approximately 5% of 
NSCLC cases with other reports of percentages between 2% to 11% of NSCLC cases 
[15, 28–33]. 
In ADCs, many studies had identified mutations in genes such as KRAS, BRAF, 
HER2 and EGFR [23, 34–38]. ALK rearrangements are more common in ADCs patients 
who are either never-smokers or light smokers [15, 39–41]. In SCC many mutations have 
also been discovered in genes such as DDR2, FGFR1/2 and genes that are part of the 
PI3K pathway  [23, 42]. 
The predictive 5-year-survival rate for NSCLC is approximately 15%, a number that 
has only improved in the past few decades [23, 43].  As it would be expected, early-stage 
tumors normally have a better clinical outcome and early stage NSCLC cases treated with 
surgical resection have a 5-year survival rate of less than 70%. Even stage I NSCLC 
patients have a risk of recurrence of approximately 30-40% [24, 32]. About a third of 
patients with stage I NSCLC can eventually die of recurrent disease despite a successful 
curative resection which demonstrates that several patients with high risk of relapse can 
also be found in early stages of NSCLC [24, 44]. The average 5-year survival rate after 
the diagnosis of advanced NSCLC is very low, only 5% for stage IIIB patients and 1% for 
stage IV patients [14, 26]. 
Nowadays, the basic histological distinction between SCLC and NSCLC is no longer 
considered sufficient to make a correct diagnosis as more specific classification of the 
tumor is possible [15, 45]. For the correct diagnosis, different approaches are needed: 
collection and analysis of non-resected small biopsy samples and cytology as well as the 
use of immunohistochemical techniques and molecular tests [14]. This allows not only to 
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distinguish ADCs from SCC, but also to detect molecular aberrations implicated in NSCLC 
pathogenesis that can help in planning of the therapeutic strategies [14]. 
The treatment of NSCLC is based on the context of the patient. Surgery is a 
possible treatment when the primary tumor is found at early stages of development [14, 
24]. However, in LC patients the standard treatment is the use of chemotherapy, although 
it is sometimes associated with resistance and toxicity [20]. When metastases are 
identified, the conventional chemotherapies remain the standard treatment in NSCLC [14, 
24]. 
Targeted therapies are also a possibility for NSCLC patients, for example: the use of 
EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib [24]. These therapies have 
shown efficacy in advanced-stage NSCLC and several studies reported that the patients 
fit for this therapies could benefit more from the use of these TKIs as a first-line treatment 
than the use of traditional platinum-based chemotherapies [15, 26]. ALK alterations such 
as EML4-ALK may also be subjected to targeted therapy with drugs such as crizotinib [15, 
24]. Finally, immunotherapies are also arising in NSCLC with Anti-CTLA-4 and Anti-PD-1 
and PD-L1 therapies having promising results [46]. 
 
 
1.4 Personalized Medicine and Pharmacogenomics 
In cancer landscape the term personalized medicine is very important due to the 
lethal characteristics of cancer, side effects of therapies and also resistance to the 
therapies that are available [21]. 
With a precise medicine, there is a customization of healthcare with medical 
decisions and approaches being directed towards the patient’s characteristics [47]. The 
goal is to tailor the diagnosis and treatment to the patient’s biological and molecular profile 
[48]. 
It becomes crucial to approach the right patient, at the right time with the right drug, 
dose and schedule [21]. But the treatment of cancer, in general, continues to be a “one 
size fits all” strategy rather than an individualize treatment [21]. One of the reasons that 
this happens is due to the actual treatment selection [21]. The tools to assess which 
patients benefit from which therapies are still lacking as the selection is normally based in 
the TNM staging system [21]. Drug resistance is another problem, even patients that 
seem to respond well to a treatment may develop resistant variants of cancer cells that 
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are no longer affected by it [49]. These variants become dominant after drug exposure 
and in some cases can be fought with second or third line options [49]. 
It becomes important to identify molecular and biological features that allow to 
predict the patient’s response to a therapy. In order to do that, more studies are required 
to correctly identify these features and translate the data into clinical practice [21].  
Most of the advances in personalized medicine in LC is happening in ADCs with 
Bevacizumab and Pemetrexed having good effective results and Erlotinib/Gefitinib and 
Crizotinib being also approved [50]. The successful development of these therapies 
proved the importance of finding markers that can be identified and targeted in order to 
achieve a new treatment. However, predictive markers of response are also very 
important and their finding can enhance the identification of patients that will actually 
benefit from many other therapies as most of first-line therapies do not have response 
predictive biomarkers identified [51]. In order to achieve that, patient-oriented tests are 
required, it is necessary to evaluate the drug sensitivity and response of the patient to 
complement the tumor’s characteristics and the presence or absence of biomarkers that 
can be targetable by therapies [51]. 
Ultimately, the interaction of genetics, epigenetics, tumor molecular biology and 
clinical and pathological criteria can result in an improved and more effective combination 
of therapies taking the patient’s characteristics into consideration as well [52]. 
 
1.4.1 Pharmacogenomics 
Understanding the molecular characteristics of both the tumor and the patient is 
essential to establish their relationship with drug response. This can be achieved by 
pharmacogenomic studies that intend to identify biomarkers that are able to predict a 
clinical outcome such as drug response [19]. 
Pharmacogenomics is seen as a highly important area, it focus on the identification 
of genetic variants that influence drug effects in the patients [19, 53, 54]. The study of 
single nucleotide polymorphisms (SNP) is an example of one of the most important type of 
studies in pharmacogenomics as many of them have identified toxicity, prognosis and 
predictive drug response markers [19, 55].  
Nowadays, dose adjustments of cytotoxic drugs are often made taking patient’s 
body surface area and response into consideration [19]. As for targeted therapies 
normally a common standard dose is given to all patients [19]. The study of biomarkers 
that can predict clinical outcomes can change this landscape [19]. 
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Pharmacogenomic studies have already found some potential biomarkers related to 
cisplatin sensitivity and targeted therapy in NSCLC [56, 57]. There are some limitations 
when translating pharmacogenomics findings into clinical practice due to, for example, the 
number of heterogeneous patients screened [58]. The development of prospective clinical 
trials in which treatments would be selected based on conventional criteria and compared 
with specific treatments for patients taking into consideration their own characteristics 
might overcome the existing reluctance in transferring novel knowledge into clinical 
practice [59]. 
Treatment efficacy will always be primary goal when making cancer therapy 
decisions and choices and in the future, the selection of an optimal and efficient treatment 
strategy for each patient will eventually be a reality [60]. 
 
1.4.2 The Contribute of Lymphoblastoid Cell Lines 
Lymphoblastoid Cell Lines (LCLs) are achieved by infecting peripheral blood 
lymphocytes with Epstein-Barr Virus (EBV), promoting their transformation and 
immortalization into LCLs [61]. Infection by EBV induces the transformation of 
lymphocytes into lymphoblastoid cells which can be an unlimited source of patient’s DNA 
and other biomolecules [62]. The use of EBV virus to transform lymphocytes is the 
method that offers the least genetic changes as the virus stays in a epissomal form inside 
the host cell [61]. The somatic mutation rate of LCLs is very low with only 0,3% and their 
maintenance is easy which makes this method a very good choice to storage patients’ 
genetic material and variability [62, 63]. The use of LCLs are reported to be fit and suitable 
for molecular and functional studies as well as genetic studies [62, 64].  
The use of LCLs from patients in genetic studies proved to be very useful and 
showed that genetic material of the patient is conserved and adequate for these studies 
[62]. Thereby, it maintains the genetic variability and is considered to be a good model to 
study drug toxicity and, at some extent, drug response [61, 65, 66]. 
However, there are some potential limitations. After two/three months in culture 
there is a risk that these cells may show alterations that are not relatable with the patients 
anymore [61, 62]. Many drug effects that are observed, cannot be translated into the 
organism as there are many interactions that are not present in a cell culture and it is 
known that LCLs do not express many CYP450 enzymes and several transporters [66, 
67]. 
In cancer landscape, LCLs have been used in genetic studies, for example, to 
evaluate the influence of SNPs in drug sensitivity and response [66, 67]. The use of LCLs 
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has proved to be a good model in phamacogenomic studies and, in many cases, have a 
successful clinical translation of what is seen in vitro [66, 67]. However, it is clear that any 
biomarker identified using this model needs to be further validated in vivo using additional 
models or samples [65].  
Ultimately, in an era where personalized medicine is becoming a reality and subject 
to many investigations, the use of LCLs may provide a valuable method to better 
understand the relationship between the patient’s characteristics and the clinical 
outcomes. This can lead to an improvement in personalized medicine as the finding of 
biomarkers related to drug toxicity and response can eventually help in the treatment 
approach by the multidisciplinary teams. 
 
 
1.5 Inflammation, Metastization and Cancer 
 
1.5.1 The Hallmarks of Cancer 
In 2011 Hanahan & Weinberg wrote a review article describing the traits and 
alterations in cell physiology that collectively lead to malignant growth and are referred to 
as Hallmarks of Cancer (Figure 4) [68]. 
 
Figure 4 – The Hallmarks of Cancer. Hanahan, D. & Weinberg, Robert A. (2011) [68]. 
During carcinogenesis the cell must acquire numerous abilities: at first it acquires 
various genetic and genomic alterations and mutations as well as many epigenetic 
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changes that lead them to aberrant phenotypes [68–70]. The cell is then able to divide, 
grow and proliferate in the absence of external growth stimuli or in the presence of 
exogenous inhibitory signals [68–70]. They can do this by promoting and inducing 
neoangiogenesis and the secretion and release of growth factors [68–70]. Eventually, they 
are able to evade apoptosis and immune system response and create an inflammatory 
microenvironment favorable for their development [68–70]. Finally, they acquire properties 
of invasion and metastization making them an even bigger threat to the organism [68–70].  
The two main hallmarks on which this project has its focus are inflammation and 
metastization. Both of them are very important in the development and progression of any 
cancer and in the case of LC, and NSCLC, inflammation and metastization are crucial to 
understand its formation, progression and mortality. 
 
1.5.2 Inflammation and Lung Cancer 
Tumor promoting inflammation is a very important characteristic. Tumors are often 
associated with infiltrated cells of the immune system and also molecules and mediators 
such as growth factors, survival factors, ECM modifying enzymes and many others that 
contribute to tumor progression [68, 71, 72].  
Inflammation is normally associated with physiological and pathological processes 
such as wound healing, tissue injury or infection [73, 74]. It is a multifactorial and complex 
response of our immune system with the objective of eliminate or neutralize any harmful 
stimuli in order to allow the healing and repairing of our tissues [73, 74].  
The relationship between inflammation and cancer is very old. In 1863 Rudolf 
Virchow already noted the presence of leukocytes in neoplastic tissues and made a 
connection between inflammation and cancer [72]. According to his hypothesis, that 
infiltration reflected the origin of cancer at sites of chronic inflammation [72]. 
About 50 years after Virchow, Paul Ehrlich suggested that the immune system could 
act against tumors [75, 76]. It could repress a potentially “overwhelming frequency” of 
carcinomas but this idea was not pursued for a long time [75, 76]. Later on, Burnet and 
Thomas supported even more this theory with their work on immunosurveillance 
hypothesis, they speculated that lymphocytes acted as sentinels in recognizing and 
eliminating continuously arising nascent transformed cells [76, 77]. 
It is known that nascent tumor cells can be eliminated by our immune system [78]. 
The interaction between the immune system and tumor suggests that at first there is an 
elimination of nascent tumor cells by the immune system followed by a stage of 
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equilibrium where the immune response can control the tumor expansion and metastasis 
and finally the escape stage where tumor cells are able to resist and evade the immune 
system response [76, 79]. 
In the tumor microenvironment, inflammation and immune system cells exhibit 
characteristics that can enhance the tumor progression, for example, the presence of  
tumor associated macrophages such as M2 macrophages capable of suppressing the 
immune system response and promote tissue remodeling and angiogenesis [80]. 
Inflammatory mediators such as chemokines and cytokines or Metalloproteinases (MMPs) 
are also present in the tumor microenvironment and are associated with many processes 
such as tumor growth, migration, invasion and metastasis [73]. The tumor infiltrating 
inflammatory cells can also release cytokines, growth factors and proteases that not only 
modulate inflammation but can also play a role in tumor progression invasion and 
metastasis [81].  
It is clear that inflammation and cancer are very tightly related in many processes of 
carcinogenesis, as it can be seen in Figure 5: Inflammation combined with oncogenic 
driver mutations lead to the activation of many inflammatory transcription factors within the 
tumor cell and tumor microenvironment [82]. Eventually, malignant cells start to produce 
inflammatory mediators leading to the recruitment of inflammatory cells into the 
microenvironment [82]. Therefore, all conditions to a cancer related inflammation are 
achieved and processes such as cell survival and proliferation, immune suppression, 
angiogenesis, migration, invasion and metastasis are influenced by this inflammatory 
microenvironment [82].   
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Figure 5 – Summary of the association between inflammation and cancer. [82] 
In summary, at very early stages of cancer development there is a proliferation of 
host immune effector populations in response to nascent transformed cells. But when the 
tumor surpasses this response and adapts to it, it creates a microenvironment that is 
favorable for its progression [83].   
 
1.5.3 Metastization and Lung Cancer 
Tissue Invasion and Metastasis is one of the most important characteristics of 
cancer development [68, 84]. Metastasis are accountable for approximately 90% of all 
cancer related deaths and thereby this process is of great importance to study it [85]. 
In 1889 Stephen Paget proposed the “seed and soil” hypothesis. From there, many 
studies were made focusing on metastization. Mechanical forces and factors were 
discovered, lymphatic and haematogeneous circulation of tumor cells were differentiated, 
host factors were also found and associated with metastasis, clonal evolution and 
heterogeneity of tumor cell populations were discovered, the origin of metastases was 
associated with a few tumor cells with specific characteristics and recently the study of 
possible therapies against metastases are being made [86, 87]. 
Metastization is a sequential and interrelated complex multistep process where each 
step is of great importance [87, 88]. The outcome depends on the cancer cell properties 
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and host response which means that there is a balance between host-tumor cellular 
interactions that vary between patients [87]. In order for cancer cells to metastasize they 
need to have some specific characteristics such as loss of cellular adhesion, increased 
invasive potential, ability to intravasate and survive in the vascular system, ability to 
extravasate and survive and proliferate in a new site [89]. 
During the metastasization process there are several steps (Figure 6), namely 1. 
Invasion and Migration: Individual metastatic cells detach from the primary tumor and 
invade an adjacent tissue. During this process many enzymes that degrade the 
Extracellular Matrix (ECM) and facilitate posterior migration are secreted 2. Intravasation: 
These cells are capable of entering blood or lymphatic vessels. The neoplastic cells 
secrete proteolytic enzymes which enable infiltration. 3. Circulation: The cells travel via 
blood or lymphatic stream and need to resist and endure that circulation and thereby 
many cells die at this point and only the “fittest” survive 4. Extravasation: Cancer cells 
leave the blood stream by penetrating the endothelium through proliferation and/or action 
of proteolytic enzymes. 5. Colonization, Proliferation and Angiogenesis. The neoplastic 
cell settles at the distant tissue site and establishes a microenvironment in order to 
proliferate and induce neoangiogenesis to ensure their survival [70, 86, 87]. It is also 
known that some cells from metastases can also metastasize again [86, 87]. 
 
Figure 6 – Schematic view of the main steps of metastization [90]. 
During metastization, Epithelial to Mesenchymal Transition (EMT) mechanisms have 
been indicated as responsible for dissemination of single tumor cells from epithelial 
tumors [91, 92]. During this process, epithelial cells undergo through various alterations 
regulated by many transcription factors, signaling pathways and mediators that end up 
promoting a transition where epithelial cells gain mesenchymal properties [70, 91, 93]. 
EMT can thereby promote invasion, metastasis, resistance to apoptosis and cell survival 
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[91, 94–99]. The mechanical forces are also important in metastization as they are 
essential for the metastatic cell to invade, metastasize and survive bloodstream [100]. 
It is known that LC cells can rapidly acquire properties that grant infiltration and 
colonization competence which can explain the short time between the primary tumor 
diagnosis and a metastatic relapse [101]. 
LCs are able to establish distant macrometastases within months of diagnosis. The 
most typical sites of metastatic relapse are: bone (34,3%), lung (32,1%) brain (28,4%), 
adrenals (16,7%) and liver (13,4%) [101–103]. 
Targeting the metastatic cell is difficult due to the genetic instability and 
heterogeneity. Ultimately, the treatment should take into consideration the characteristics 
of metastatic cells and also the characteristics of the host microenvironment [104]. 
 
 
1.6 Metalloproteinases and Tissue Inhibitors of Metalloproteinases  
MMPs were identified in 1962 by Gross and Lapiere. Their study described the 
ability of a soluble factor to lyse purified collagen ex vivo [105, 106]. Since then, this family 
of endopeptidases has been studied and vast information has been discovered about 
them and their function [105]. During the years, they began to be associated with many 
pathologies and eventually were associated with tumors and metastasis [105].  
MMPs are classified as a calcium dependent, Zn2+ containing endopeptidases and 
can be found in a soluble form or a membrane-bound form [105]. There are 23 human 
MMPs that can be divided into different groups such as collagenases, gelatinases, 
stromelysins, matrylisins, elastases and membrane-type MMPs [105, 107–109]. 
Collectively, they are normally called matrixins and participate in ECM degradation [110–
112]. They are also important in tissue homeostasis, host defense, tissue remodeling and 
repairing, inflammation and many other processes [107, 113]. Their natural inhibitors, the 
Tissue Inhibitors of Metalloproteinases (TIMPs) are specific inhibitors that regulate and 
control their activities [110, 114]. 
Their structure is complex (Figure 7), they contain several domains: a predomain, a 
propeptide domain, a catalytic domain and a hemopexin domain [115]. They also require 
zinc in their catalytic domain and are synthetized as inactive zymogens that need to be 
activated [115, 116]. 
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Figure 7 – Overview on MMPs’ structure. [115] 
 
The proteolytic activation of MMPs allows the propeptide, called pro-MMP, to 
achieve its active form [110]. The process of activation ends up with the removal of the 
propeptide by intermolecular processing [110, 117]. Other processes such as plasmin 
activation, intracellular activation or cell surface activation can also activate MMPs [110]. 
The proteolytic activity of MMPs is normally very low in healthy tissues, their 
transcription levels can be upregulated by action of inflammatory cytokines and growth 
factors and their expression can also be regulated by hormones, tumor promoters, cell-to-
cell and cell-to-ECM interactions [107].  
TIMPs can bind to MMPs in order to regulate their activity, there are four TIMPs 
(TIMP-1-4) identified in vertebrates and their expression is normally upregulated during 
tissue remodeling [110, 114]. Because of their importance in regulating MMPs’ activities, 
their analysis in pathological conditions associated with MMPs is also important [110]. In 
fact, TIMPs can form complexes with pro-MMPs in order to regulate their action [118].  
 
1.6.1 MMPs, TIMPs and Lung Cancer 
At first MMPs were believed to facilitate metastasis by breaking down physical 
barriers provided by ECM. But actually, their action in carcinogenesis is important in many 
other processes such as growth, apoptosis and angiogenesis (Figure 8) [115, 119].  
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Figure 8 – Summary on MMPs’ activities and their role in carcinogenesis. Adapted from Hua, H., et 
al. (2011) [81]. 
It is clear that cancer cells are able to stimulate host cells to be a great source of 
MMPs [120]. MMPs are able to regulate tumor growth by different mechanisms as  they 
can disrupt the balance between growth and anti-growth signals in the tumor 
microenvironment due to their potential to influence the bioavailability and functionality of 
multiple factors [115, 121, 122].  
In the apoptotic process MMPs can either have apoptotic or anti-apoptotic roles 
[115, 120]. They can interfere with the induction of apoptosis in malignant cells and can 
lower the impact of chemotherapy on the tumor [122]. 
MMPs are also capable of regulate angiogenesis [119] . Once more, MMPs play a 
dual role in angiogenesis as they can either promote or inhibit angiogenesis through their 
activity which can promote the release of both pro and anti angiogenic factors [81, 115, 
120, 122–126]. 
The overexpression and high activity levels of MMPs are usually associated with 
tumor progression [81]. Downregulation of TIMPs may result in an increase of MMPs’ 
activities and thereby a more invasive potential for tumor cells [81]. However, upregulation 
of TIMPs can actually inhibit tumor invasion and metastasis [81]. TIMPs can participate in 
many processes of carcinogenesis and commonly act as tumor suppressive agents being 
dysregulated in many cancers [81]. 
Tumor cells can produce pro-inflammatory factors and MMPs which can induce an 
influx of inflammatory cells to the site of the tumor contributing for its progression [119]. 
39 
 
Elevated expression and activity of MMPs can be observed in acute or chronic 
inflammation [81]. They exhibit either pro-inflammatory or anti-inflammatory activities 
depending on the characteristics and context of the environment [81, 127].  
MMPs that degrade ECM may also affect the immune system as some of the 
proteolytic fragments that result from that process can exert chemotactic properties [122, 
128].  
Usually, the expression of MMPs in primary tumor sites is increased and can be 
found in the invasive front or leading edge of the tumor which can be explained by their 
proteolytic activity which is essential to allow the malignant cells to break physical barriers 
during expansion, intravasation, extravasation and invasion [115, 119, 120].  
MMPs are therefore associated with cell movement due to their proteolytic functions 
as they can regulate cell-cell and cell-ECM interactions [120]. The production of peptides 
in the process of degradation of ECM components can also promote cell migration [120, 
129–131]. 
MMPs have also been associated with EMT [120, 121]. This happens due to their 
proteolytic activity an ability to cleave ECM components [115, 120, 132, 133]. 
They have many roles in carcinogenesis making them potential therapeutic targets. 
However, their dual roles in carcinogenesis and importance in the homeostasis of normal 
tissues difficult this option [120]. 
 
1.6.2 MMP-2, MMP-7, TIMP-2 and TIMP-4  
In this work, MMP-2, MMP-7, TIMP-2 and TIMP-4 were studied in the context of 
NSCLC. 
MMP-2 (gelatinase A) is associated with many pulmonary diseases [134, 135]. It is 
capable of degrading a variety of ECM components and is often associated with 
angiogenesis, cell invasion, migration and induction of EMT. Therefore it is considered to 
be important in the process of metastization and inflammation and is related to advanced 
stage and poor prognosis in cancer [81, 120, 122, 136]. It is also capable of suppressing 
the T-lymphocyte proliferation and reaction against cancer cells [120]. MMP-2 has also 
been associated with tumor growth and dampen inflammatory properties  [81, 107, 113, 
127, 137]. It can influence the migration of some immune system cells such as leukocytes 
and is associated with pro-inflammatory processes [81, 107, 138].  
In NSCLC, high expression of MMP-2 in tumor and peritumoural cells and high 
serum levels in patients with metastases were associated with invasion, metastasis, 
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increased risk of tumor recurrence and poor prognosis [139–141]. Its overexpression in 
tumor tissue of patients at an early stage was also observed and related to poor prognosis 
[142]. MMP-2 expression in NSCLC patients with lymph node metastasis was significantly 
higher than in patients without lymph node metastasis [140]. 
MMP-7 (matrylisin) is a proteolytic enzyme responsible for the destruction of ECM 
and basement membrane components and can be produced by tumor cells. It has been 
associated with tumor progression, apoptosis, invasion and metastasis [143–145].  
In NSCLC, high expression of this MMP in tumor cells is common as well as high 
levels of MMP-7 mRNA in tumor tissue [143, 145, 146]. This MMP has been associated 
with chemotherapy response with its overexpression in tumor samples being related with 
poor response to platinum-derived chemotherapy [144]. It was also considered to be an 
independent predictor of prognosis in NSCLC patients with overall survival being 
considerably lower in patients with high MMP-7 expression [144]. A high enzymatic 
activity by MMP-7 was also found in tumor tissue [145].  
In regard of TIMPs, it is known that both MMP-2 and MMP-7 can be inhibited by 
TIMP-2 and TIMP-4 [81, 118, 135, 147–149]. Both of them can inhibit tumor growth in 
vitro and in vivo which would be expected from their ability to inhibit MMPs [150]. 
TIMP-2 is a multifunctional protein secreted into ECM. Usually, its high levels are 
associated with a favorable prognosis in NSCLC due to its association with the inhibition 
of endothelial cell proliferation, migration and angiogenesis [150, 151]. Its overexpression 
has already been associated with inhibition of tumor growth, invasion and metastasis due 
to their MMP inhibitory activity [150, 152]. High TIMP-2 expression is not only related to 
the outcome at early-stage NSCLC, being considered a favorable factor, but is also 
associated with the outcome at late stages of the disease [151]. The absence of this TIMP 
accelerated tumor growth and stimulated mediators of angiogenesis and inflammation 
[153]. Serum levels of TIMP-2 have also been found to be significantly lower in NSCLC 
patients than in controls [152]. 
TIMP-4 is the most recent member of the TIMP family. In normal conditions, it is 
only abundantly expressed in human cardiovascular structures [154]. In the lung, it can be 
expressed by epithelial and plasma cells and interstitial macrophages [134]. This TIMP 
was already associated with inflammatory diseases [154]. A study of idiopathic pulmonary 
fibrosis observed its expression in macrophages and plasma cells [155]. In cancer 
landscape, studies in vitro and in vivo have demonstrated TIMP-4 potential to inhibit cell 
invasiveness, metastatic potential, angiogenesis and tumor growth and can sensitize 
cervical cancer cells to an apoptotic death [150, 156–159]. In breast cancer cell lines, the 
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induction of an overexpression of this TIMP was reported to inhibit in vitro growth rates, 
invasive potential and eventually, in vivo tumorigenicity and metastasis [158].  
Taking into consideration what has been described, it becomes interesting to better 
understand the relationship between these MMPs and TIMPs and NSCLC. Based on their 
activity and influence in many processes such as inflammation and metastization, there is 
much potential in MMPs and TIMPs yet to be investigated particularly in NSCLC. 
 
  
  
Chapter 2 
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2 Aims  
 
2.1 Main Objectives 
 
1. Study the importance and relevance of circulating markers of inflammation and 
metastization (MMPs and TIMPs) in the NSCLC landscape. 
2. Evaluate if the use of LCLs from patients is a good model to study the influence of 
MMP-2, MMP-7, TIMP-2 and TIMP-4 in NSCLC. 
 
2.2 Secondary Objectives  
 
1. Study the importance and relevance of MMPs and TIMPs in the NSCLC 
landscape. 
2. Relative quantification of MMP-2, MMP-7, TIMP-2 and TIMP-4 mRNA levels in 
patients with NSCLC and controls before and after the immortalization technique. 
3. Comparison between the mRNA levels of MMP-2, MMP-7, TIMP-2 and TIMP-4 
before and after the technique of immortalization. 
4. Comparison between the mRNA levels of MMP-2, MMP-7, TIMP-2 and TIMP-4 in 
NSCLC patients and controls before and after the technique of immortalization. 
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3 Materials and Methods  
 
3.1 Patient Selection 
The patient selection criteria for this study was the following: adult patients 
diagnosed with NSCLC by either histological or cytological methods, at any TNM stage 
and without any oncological treatment regime or medical intervention. These patients 
were diagnosed and recruited to this study from the Service of Medical Oncology at 
Centro Hospitalar do Porto between May and August of 2016. Their clinical and 
demographic information was collected from the medical records. 
Three controls without any known oncological pathology, residing within the Porto 
residence area were also recruited for this study from Centro Hospitalar do Porto. 
All the participants gave their consent to be included in this study according to the 
Helsinki declaration. 
 
3.2 Sample Collection and Processing 
Blood samples were collected from all participants using the standard intravenous 
collection method. Approximately 8mL of peripheral blood was collected into EDTA and 
CPT collection tubes.  
EDTA collection tubes were then processed with centrifugations at 10 minutes and 
2500 rpm until the peripheral blood cells were separated and then conserved in Tripure® 
(Roche) at -80ºC. The CPT collection tubes were centrifuged during 30 minutes at 3000 
rpm in order to separate the peripheral blood mononuclear cells (PBMCs) from the 
patients’ blood. 
 
3.3 B95-8 Cell Culture and Lymphoblastoid Cell Lines from Patients 
In order to study the possible relationship between the molecular targets of interest 
(MMPs and TIMPs) and NSCLC and possible clinical outcomes, such as treatment 
toxicity, response or prognosis, it was used the LCLs model. 
In this project B95-8 cells (ATCC®, VR-1491) were used in order to have enough 
supply of EBV virus. B95-8 cell lines were put in culture medium constituted by RPMI 
1640 Medium + 20% FBS and 1% Penicillin – Streptomycin.  
The PBMCs previously isolated from patients’ blood samples were put in contact 
with the supernatant from the B95-8 cell culture which had the EBV necessary for the 
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immortalization technique and then were put with “transformation” culture medium 
containing RPMI 1640 Medium + 20% FBS and 1% Penicillin – Streptomycin + 400ng/mL 
of cyclosporine.  At approximately 30 days of culture, a pellet of LCLs’ cells was made 
through a 5 minutes at 1500 rpm centrifugation and preserved in Tripure® (Roche) at -
80ºC. 
 
3.4 RNA extraction and cDNA synthesis 
RNA was extracted from the patients’ peripheral blood cells and LCLs’ pellet, both 
preserved in Tripure® using the GeneJet RNA Purification Kit (Thermo Scientific ®) and 
following manufacturer’s instructions. The purity of the isolated RNA was measured at 260 
nm and 280 nm using NanoDrop ® spectrophotometer. 
After that, mRNA samples were used as template for the cDNA synthesis using the 
High capacity RNA-to-cDNA Kit (Applied Biosystems ®) according to manufactures’’ 
instructions. 
 
3.5 Relative Quantification of MMP-2, MMP -7, TIMP-2 and TIMP-4  
The relative quantification of the transcript levels of MMP-2, MMP-7, TIMP-2 and 
TIMP-4 was made by Quantitative Real-Time PCR. The reactions were made in a 7500 
Fast Real Time PCR system (Apllied Biosystems ®) with the following resources: 1x 
MasterMix (Applied Biosystems ®), 1x probes (Taqman ® Gene Expression Assay – 
Hs01548727_m1 MMP-2; Hs01042796_m1 MMP-7; Hs00234278_m1 TIMP-2 and 
Hs00162784_m1 TIMP-4 - Applied Biosystems ®), cDNA samples from patients’ 
peripheral blood cells and LCLs and β2M endogenous control (β2M Oligo Mix 
(REF:4332653) - Applied Biosystems ®) in order to normalize the results observed. 
Data analysis was made using 7500 Software v2.0.3 (Applied Biosystems ®) with 
the same baseline and threshold for each sample in order to have threshold cycle (Ct) 
values for all samples. The quantification of MMP-2, MMP-7, TIMP-2 and TIMP-4 and 
β2M was performed in duplicate and negative controls lacking samples were also 
included. 
 
3.6 Statistical Analyses  
All the statistical analyses were made using IBM® SPSS® statistics software v 23.0 
for Windows ®. The t´Student test and Livak method (2-ΔΔCT) were used to analyze and 
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evaluate differences between the mRNA normalized expression levels, ρ-values under 
0,05 were considered to be statistically significant. 
The real-time PCR assays originated Ct (cycle threshold) values for each 
combination of assay-sample. These values are correspondent to the cycle number of the 
early exponential phase of the amplification reaction and, therefore, are inversely 
proportional to the relative expression levels or quantity of the targets in the sample 
tested. Thus, the mean of the Ct values within each sample type was determined and, in 
order to normalize the results, the difference between the mean Ct values of the target 
and the mean Ct values of endogenous control (β2M) was assessed. This number is 
designated as the ΔCt. The fold change values were calculated by formula 2-ΔΔCT, 
following Livak et al. (2001) [160]. 
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4 Results 
 
 
4.1 Patients Information 
From the patients selection, a total of 16 NSCLC patients, 13 males and 3 females 
with ages between 39 and 80 years old, a mean of approximately 63 years old (±10,856), 
all Caucasians from the North Region of Portugal were recruited. All the clinical, 
pathological and demographic information is described in Table 1. 
 
Table 1 - Clinical, Pathological and Demographic characteristics of the NSCLC 
cases group. 
      Mean   Std. Deviation 
            
Age at Diagnosis 
  
63,44 
 
10,856 
            
            
      n (n=16)   % 
Gender            
  Masculin 
 
13 
 
81,25 
  Feminin 
 
3 
 
18,75 
  Total   16   100,00 
Smoking           
  Non-Smokers  
 
3 
 
18,75 
  Ex-Smokers 
 
6 
 
37,50 
  Smokers 
 
7 
 
43,75 
  Total   16   100,00 
TNM Stage           
  IIIA 
 
2 
 
12,50 
  IIIB 
 
3 
 
18,75 
  IV 
 
10 
 
62,50 
  No Information 
 
1 
 
6,25 
  Total   16   100,00 
Histology           
  Adenocarcinoma 
 
12 
 
75,00 
  Squamous Cell Carcinoma 
 
4 
 
25,00 
  Total   16   100,00 
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4.2 mRNA Relative Quantification levels of MMP-2, MMP-7, TIMP-2 and TIMP-4 
Before and After Immortalization  
 
4.2.1 Relative Quantification of mRNA levels of MMP-2, MMP-7, TIMP-2 and TIMP-4  
in NSCLC cases: Before and After Immortalization 
At first the NSCLC cases group was evaluated and the relative quantification of 
mRNA levels of MMP-2, MMP-7, TIMP-2 and TIMP-4 before and after the immortalization 
technique was done in order to understand if the use of this technique would induce 
significant changes in the mRNA levels of our molecular targets. 
The mRNA levels of MMP-2 were significantly higher after the immortalization 
technique (ρ=0.006). The mRNA levels of MMP-7 appear to be lower after 
immortalization. However, this difference cannot be considered to be significant 
(ρ=0.765). As for the mRNA levels of TIMP-2, after the technique of immortalization the 
levels were increased but the change was not significant (ρ=0.220). Finally, the mRNA 
levels of TIMP-4 were lower after the immortalization although that difference was not 
significant (ρ=0.090).  
  
Figure 9 – mRNA Relative Quantification levels of MMP-2 and MMP-7 before and after the 
immortalization technique in NSCLC cases (-ΔCT). 
 
ρ=0.006 ρ=0.765 
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Figure 10 – mRNA Relative Quantification levels of TIMP-2 and TIMP-4 before and after the 
immortalization technique in NSCLC cases (-ΔCT). 
In order to understand the magnitude of these differences the Fold Changes were 
made (Table 2) and according to them the significant change observed between the 
MMP-2 levels before and after immortalization corresponds to an increase of the 
expression levels after the immortalization technique as it was portrayed in Figure 9. The 
changes observed for the MMP-7 and TIMP-4 indicate higher levels of these targets 
mRNA before the immortalization technique and TIMP-2 mRNA levels are lower before 
the technique. Apart for the MMP-2 levels all the other changes were not statistically 
significant. 
Table 2 – Fold Changes of MMP-2, MMP-7, TIMP-2 and TIMP-4 mRNA levels between 
before and after the immortalization technique in NSCLC cases (2 -^ΔΔCT). 
Immortalization MMP-2 MMP-7 TIMP-2 TIMP-4 
     
Before vs After 
0.012 
(ρ=0.006) 
1.410 
(ρ=0.765) 
0.338 
(ρ=0.220) 
3.662 
(ρ=0.090) 
 
 
4.2.2 Relative Quantification of mRNA levels of MMP -7 and TIMP-2 in 
controls: Before and After Immortalization  
As it happened with the NSCLC cases group, the control group was also evaluated 
for mRNA levels of our molecular targets due to the importance of clarifying if the 
presence of NSCLC had any influenced in the changes between the levels before and 
after immortalization. The relative quantification of mRNA levels of MMP-2, MMP-7, TIMP-
2 and TIMP-4 in controls was made before and after the immortalization technique. 
ρ=0.220 ρ=0.090 
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However, the mRNA levels of MMP-2 and TIMP-4 could not be compared due to the lack 
of data. 
The mRNA levels of MMP-7 were found to be higher after the immortalization in 
controls. However, that difference was not significant (ρ=0.365). The difference registered 
between the levels of TIMP-2 before and after immortalization was found to be statistically 
significant (ρ=0.001), it was registered an increase of mRNA TIMP-2 levels after the 
immortalization technique.  
 
Figure 11 - mRNA Relative Quantification levels of MMP-7 and TIMP-2 before and after the 
immortalization technique in controls (-ΔCT). 
Once again, in order to understand the magnitude of these differences the Fold 
Changes were also made for the controls group (Table 3) and indicated that the significant 
change observed in the TIMP-2 mRNA levels before and after immortalization 
corresponds to an increase of the expression levels after the immortalization technique as 
it was portrayed in Figure 11. The changes observed for MMP-7 indicated lower levels of 
mRNA before the immortalization technique but the difference was not significant. 
Table 3 –Fold Changes of MMP-7 and TIMP-2 mRNA levels between before and after 
the immortalization technique in controls (2 -^ΔΔCT). 
Immortalization MMP-2 MMP-7 TIMP-2 TIMP-4 
     
Before vs After * 
0.016 
(ρ=0.365) 
0.057 
(ρ=0.001) 
* 
*- Not enough data. 
ρ=0.365 
ρ=0.001 
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4.2.3 Relative Quantification of mRNA levels of MMP -7 and TIMP-2 in 
NSCLC cases and Controls: Differences between NSCLC cases and 
Controls before and after Immortalization  
The comparison between controls and NSCLC cases was made taking into 
consideration the mRNA levels of MMP-7 and TIMP-2 before and after the immortalization 
technique in both groups. 
According to Figure 12, the mRNA levels of MMP-7 and TIMP-2 before the 
immortalization were slightly higher in controls compared to NSCLC cases but none of 
these differences were significant. After the immortalization technique the levels of MMP-7 
and TIMP-2 were also found to be higher in controls when compared to NSCLC cases 
and the difference between the TIMP-2 mRNA levels in controls and NSCLC cases 
registered after immortalization was considered to be statistically significant (ρ=0.007). 
  
 
  
Figure 12 - mRNA Relative Quantification levels of MMP-7 and TIMP-2 in controls and NSCLC 
cases before and after the immortalization technique (-ΔCT). 
ρ=0.266 ρ=0.060 
ρ=0.098 ρ=0.007 
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 The fold changes were also made to better understand the differences between 
controls and NSCLC cases before and after the immortalization technique (Table 4). Once 
more, what was portrayed in Figure 12 was confirmed with this test: mRNA levels of 
MMP-7 and TIMP-2 before immortalization were found to be higher in controls compared 
to NSCLC cases but were not significant. mRNA levels of MMP-7 and TIMP-2 after 
immortalization were also found to be increased in controls when compared to NSCLC 
cases and the TIMP-2 difference was statistically significant. 
Table 4 – Fold Changes of MMP-7 and TIMP-2 mRNA levels between controls and 
NSCLC cases before and after the immortalization technique (2 -^ΔΔCT). 
Immortalization MMP-2 MMP-7 TIMP-2 TIMP-4 
Before     
Controls vs 
Cases 
* 
3.062 
(ρ=0.266) 
1.804 
(ρ=0.060) 
* 
After     
Controls vs 
Cases 
* 
336.695 
(ρ=0.098) 
10.677 
(ρ=0.007) 
* 
*- Not enough data. 
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5  Discussion 
 
5.1 Changes in the mRNA MMP-2, MMP-7, TIMP-2 and TIMP-4 levels before and 
after Immortalization in NSCLC cases and in controls 
As it was described, both the NSCLC cases and controls were submitted to a 
relative quantification of the mRNA levels of MMP-2, MMP-7, TIMP-2 and TIMP-4 before 
and after the immortalization technique in order to understand if the use of LCLs from 
NSCLC patients would be a good predictive model to study the importance of these 
molecular targets in the NSCLC landscape namely in drug sensitivity and response. 
The mRNA levels of MMP-2 were significantly higher after the immortalization 
technique (ρ=0.006) in the NSCLC cases group. This could be explained due to the 
changes in the cell biology and behavior that happen when peripheral blood cells undergo 
through EBV transformation in order to become a LCL from the patient [61]. It is 
documented that EBV transformation and culture cell processes can induct cellular and 
molecular changes such as growth rate and according to this finding the transformation 
can eventually enhance the cell invasion and metastatic potential due to the difference 
registered in the MMP-2 mRNA levels considering that this MMP has been associated not 
only with tumor growth but also with invasion, angiogenesis and metastasis  [65, 66, 81]. It 
is important to notice that in a study of human lymphoproliferative diseases, 
lymphoblastoid cells were reported to be associated with an increase expression and 
secretion of MMP-2 and MMP-9 and that was related with invasive, angiogenic and 
metastasis abilities of these cells [161]. This hypothesis would need further studies to 
evaluate if the activity of this MMP in LCLs is related to an invasive and metastatic 
potential of lymphoblastoid cells or its actions do not promote those characteristics in 
these cells. Another aspect that may be important is that the use of EBV can induce 
inflammation and the increased levels of MMP-2 after immortalization may suggest that 
this MMP may be related with that process. 
The mRNA levels of MMP-7 appear to be lower after EBV transformation in the 
NSCLC cases group although it is not a significant change (ρ=0.765). This MMP has also 
been associated with tumor progression, invasion and metastasis  [143, 146]. However, in 
this case the results suggest that the immortalization technique does not alter the levels of 
this MMP to a point where the differences between before and after immortalization are 
significant. This means that in LCLs, MMP-7 could probably be studied in order to 
evaluate its influence in drug sensitivity tests and response. 
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TIMP-2 mRNA levels were found to be increased after immortalization in NSCLC 
cases group but without statistical significance (ρ=0.220). This result suggests that the 
mRNA levels of this TIMP-2 were not greatly altered in the NSCLC cases group by the 
immortalization technique. 
The TIMP-4 mRNA levels after immortalization appeared to be lower than before 
immortalization but without any statistical significance (ρ=0.090) in the NSCLC cases 
group. This result suggests that the levels of TIMP-4 are not greatly altered by the 
immortalization technique and therefore it may be possible to study this TIMP and its 
action in LCLs. 
In the controls group the levels of MMP-2 and TIMP-4 mRNAs were not evaluated 
as there was not enough data for a correct analysis. 
As for MMP-7, it was observed that in the controls group the levels of MMP-7 
increased after the immortalization technique, although that difference was not significant 
(ρ=0.365). As it happened with the NSCLC cases group, the changes registered of this 
MMP before and after immortalization were not significant and that can indicate that this 
MMP can be studied in the context of a LCL based investigation.  
The TIMP-2 mRNA levels were found to be significantly higher after the 
immortalization technique (ρ=0.001) in the controls group. This time, the results were 
considered to be significant and suggest that EBV transformation can eventually promote 
changes in the expression of mRNA levels of TIMP-2 therefore altering the cell behavior 
and offering a barrier to the study of this TIMP in a LCLs context. High levels of TIMP-2 
were already associated with the inhibition of angiogenesis, tumor growth, invasion and 
metastasis [150–152]. If the EBV transformation induces a process similar to 
carcinogenesis, this increase of TIMP-2 mRNA levels may be an attempt to regain 
homeostasis. 
  
 
5.2 Comparison of the mRNA levels of MMP-7 and TIMP-2 between controls and 
NSCLC cases before and after Immortalization 
After the measure of mRNA levels of our molecular targets in both the NSCLC 
cases group and controls group it became interesting to evaluate the differences between 
controls and NSCLC cases in the targets available for both of them before and after the 
Immortalization technique. 
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mRNA levels of MMP-7 were found to be higher in controls than in NSCLC cases 
before (ρ=0.266) and after (ρ=0.098) the immortalization technique but none of those 
differences were considered to be statistically significant. Before immortalization, the 
difference registered is interesting as MMP-7 is usually related with tumor progression, 
invasion and metastasis and in this study its levels are not higher in the NSCLC cases 
group comparing to the controls group. After the transformation, the changes were 
concordant with the previous data: in NSCLC cases there was a decrease of MMP-7 after 
immortalization and in controls there was an increase, both without statistical significance. 
When comparing both groups after immortalization the controls had higher levels than 
NSCLC cases. It is important to notice that these changes were not significant. 
As for the mRNA levels of TIMP-2, there were higher levels in the control group 
before (ρ=0.060) and after (ρ=0.007) the immortalization technique in comparison with the 
NSCLC cases group. The difference observed before immortalization was not significant 
but it demonstrates a statistical tendency that may indicate that lower levels of circulating 
TIMP-2 are present in NSCLC patients in comparison with controls. Taking into 
consideration the action of TIMP-2 in inhibiting MMPs and its relation with the inhibition of 
tumor growth, invasion and metastasis it becomes understandable that this difference 
may represent an unbalance in NSCLC patients between MMPs/TIMPs. In fact, serum 
levels of TIMP-2 were already reported to be lower in NSCLC patients than in controls 
[152]. After the immortalization technique the difference between NSCLC cases and 
controls was significant. This difference may represent the effects of the immortalization 
technique in TIMP-2 levels. As it was described earlier, the difference between NSCLC 
cases and controls before the immortalization was not significant but after that technique it 
became significant, which shows that the EBV transformation may greatly alter the 
expression of this TIMP because even though the number of controls is limited we are 
referring to the control group in all the relative quantifications and therefore if EBV 
transformation had no part in altering these levels the difference registered after the 
immortalization would not be significant as it happened before the immortalization. This 
result suggests that TIMP-2 levels in LCLs are altered and the study of the influence of 
this TIMP in a LCL based project may not relate to what happens in the organism.  
 
 
5.3 Limitations of LCLs and their association with MMPs 
It is reported that LCLs from patients may present a somatic mutation rate of 0.3% 
and the whole exome and genome sequencing have shown 99% concordance in DNA 
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sequence between LCLs and peripheral blood cells from the same individual [63, 65]. 
LCLs provide an unlimited source of biomolecules such as DNA, RNA or proteins and 
taking into consideration the similarity described before, it is possible to consider this 
model to be useful in many pharmacogenomic studies and also immunology and cellular 
biology studies [61]. 
However, normal peripheral blood lymphocytes undergo significant transformation to 
become “immortal” and originate LCLs and that can alter the biology and metabolism of 
the cell. That must be considered relevant and important in the interpretation of any study 
that involves the use of LCLs [61]. EBV transformation and cell culture processes might 
introduce cellular changes such as growth rate that can be responsible for the difficulties 
encountered when trying to access a biomarker´s importance and influence found in LCLs 
models in clinical studies and functional assays meaning that phenotypes that are found in 
vitro may not be observed in vivo [65, 66] .  
Although the role and potential alteration of MMPs and TIMPs in LCLs has yet to be 
discovered, some associations between EBV and MMPs have already been reported. 
The latent membrane protein 1 (LMP1) of EBV is crucial in cell immortalization [61]. 
It aggregates cellular proteins of the TNF receptor signaling pathway to active 
transcription factor NF-κB [61]. In sinonasal squamous cell carcinomas, the presence of 
EBV and LMP1 positive patients was related with lymph node or distant metastasis [162]. 
Induction of MMP-1 and MMP-3 was also detected in nasopharyngeal cancer patients 
with LMP1 positive tumors compared with other head and neck cancer patients. The 
expression of MMP-3 was also associated with initial stages of carcinogenesis and tumor 
progression [163]. Zta, a lytic transactivator of EBV, has been shown to promote migration 
and invasion of epithelial cells and once again MMP-3 and MMP-9 were essential for Zta-
induced cell invasion [164]. The invasive potential of an EBV positive LCL (NC-37, a 
Burkitt’s lymphoma cell line used as a target cell for EBV infection studies) was also 
studied in vitro and in this case MMP-2 expression was related with the invasive potential 
of this cell line [165]. Finally in human lymphoproliferative diseases, lymphoblastoid cells 
have also been associated with an increase in expression and secretion of MMP-2 and 
MMP-9 and  with invasive, angiogenic and metastasis behaviors [161]. 
In this study, it was observed that the immortalization technique using EBV in order 
to have LCLs may greatly alter the mRNA levels of MMP-2 and TIMP-2 and therefore the 
investigation of these biomolecules in drug sensibility and response using LCLs may not 
be possible due to the changes that this transformation causes. This can also represent a 
possible limitation for LCLs studies as the behavior and environment of lymphoblastoid 
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cells are not similar to the initial patients’ cells and it is known that many LCLs studies do 
not have a successful translation into clinical practice. For MMP-7 and TIMP-4 the 
changes were not significant which means that it may be possible to s tudy these 
biomolecules in a LCL based study.  
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6  Conclusions and Future Perspectives 
 
The results from this study suggest that the mRNA levels of MMP-2 and TIMP-2 are 
significantly altered by the immortalization technique used which means that the use of 
EBV in order to transform and immortalize the patients’ peripheral blood lymphocytes in 
order to have LCLs may induce alterations in the bioavailability of these biomarkers. For 
the first time, to our knowledge, the levels of mRNA of MMP-2, MMP-7, TIMP-2 and TIMP-
4 were evaluated in a LCL based study and the comparison between before and after the 
immortalization technique was made. 
Due to the activity of MMP-2 and its association with cell growth, invasion and 
metastization, it seems that this technique can not only promote the growth of these cells 
but also an invasive and metastatic behavior on lymphoblastoid cells meaning that this 
technique may induce processes similar to carcinogenesis. However, this could only be 
validated in future studies by the evaluation of MMP-2 protein levels using other 
techniques such as ELISA in order to understand if the mRNA levels are associated with 
the actual protein levels. As for the processes that may be induced by EBV, levels of 
inflammatory and angiogenic mediators as well as cell growth rates could indicate if the 
processes that happen in LCLs may be similar to those that happen in carcinogenesis. 
The higher mRNA levels of TIMP-2 in controls compared to NSCLC patients before 
the immortalization were very close to be significant (ρ=0.060) and demonstrates a 
statistical tendency which would be expected as TIMPs levels in cancer patients are 
reported to be usually lower whereas MMPs levels tend to be higher. After the 
immortalization the difference was significant suggesting that TIMP-2 levels are actually 
altered by this technique and the increase of mRNA levels of TIMP-2 after the 
immortalization technique in controls is proof of that significant difference. To validate 
these findings, the evaluation of TIMP-2 protein levels using, for example, ELISA, could 
indicate if the differences of mRNA levels are actually accompanied by differences in the 
actual protein levels. 
However, the changes registered in the mRNA levels of MMP-7 and TIMP-4 were 
not significant leaving the possibility for them to be studied in the context of a LCL based 
study. This can also mean that some MMPs and TIMPs such as MMP-2 and TIMP-2 tend 
to be more important in carcinogenesis: if the transformation by EBV virus induces 
processes similar to those that happen in carcinogenesis the difference registered can be 
an indicator that MMP-2 and TIMP-2 play more important roles in these processes than 
MMP-7 and TIMP-4. 
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In summary, the potential influence of MMPs and TIMPs in drug sensitivity and 
response is still possible to be studied as they are very important in many processes of 
carcinogenesis. However, the use of LCLs towards that objective may offer potential 
limitations as changes between before and after immortalization are registered indicating 
that this method promotes differences between what is seen in vivo and what is observed 
in vitro. This study provided more insight on what happens in LCLs and can indicate a 
possible reason why the findings in LCLs studies are difficult to be translated into clinical 
practice. 
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